Sign In
Buy ERAS
$18.53
-0.650 (-3.39%)
At Close: Jul 10, 2026
Stock Traders Buy Large Volume of Erasca Call Options (NASDAQ:ERAS)
04:34am, Thursday, 12'th Feb 2026
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) saw some unusual options trading on Wednesday. Investors bought 4,075 call options on the stock. This is an increase of approximately 104% compared to the
Erasca to Present at Upcoming Conferences in February
08:00am, Thursday, 05'th Feb 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?
07:52am, Monday, 26'th Jan 2026
Erasca Inc. (NASDAQ: ERAS) stock is trading lower on Monday, though there is no news to justify the movement.
SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca Announces Pricing of Upsized Public Offering of Common Stock
08:54pm, Wednesday, 21'st Jan 2026
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca, Inc. (NASDAQ:ERAS) Sees Large Increase in Short Interest
03:20am, Wednesday, 21'st Jan 2026
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 20,487,523 shares, a growth of 20.8% from t
Erasca Announces Proposed Public Offering of $150 Million of Common Stock
04:01pm, Tuesday, 20'th Jan 2026
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca Stock Surges 42% in a Week: Here's What You Should Know
10:10am, Friday, 16'th Jan 2026
ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment.
David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7
04:12pm, Thursday, 15'th Jan 2026
The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise.
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
10:52am, Wednesday, 14'th Jan 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion
Erasca Insider Sells $671K as Stock Jumps 189% This Past Year
02:53pm, Tuesday, 13'th Jan 2026
Erasca's general counsel and corporate secretary sold 120,000 shares of the biotech for $670,800 in gross proceeds on Jan. 7. The sale resulted from an option exercise with shares immediately sold; no
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
08:00am, Monday, 12'th Jan 2026
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for E
Ebun Garner Sells 120,000 Shares of Erasca (NASDAQ:ERAS) Stock
05:22am, Saturday, 10'th Jan 2026
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) General Counsel Ebun Garner sold 120,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an a
What's Going With Cancer Biotech Erasca Stock On Thursday?
01:21pm, Thursday, 08'th Jan 2026
Erasca Inc. (NASDAQ: ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33.
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 06'th Jan 2026
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
